Skip to content

Pro-Dex, Inc. PDEX Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Medtronic logo
MedtronicMDT
InfuSystem Holdings logo
InfuSystem HoldingsINFU
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
UFP Technologies logo
UFP TechnologiesUFPT
Artivion logo
ArtivionAORT
IAR
Integra LifeSciencesIART

Other financials

Income statement

See full
Revenue$19.9M+14.6%
Gross profit$6.1M+5.8%
Operating income$3.1M-15.0%
Net income$3.9M+20.2%
EPS (diluted)$1.20+22.4%

Balance sheet

See full
Cash & equivalents$10.0M+123%
Total debt$16.0M+43.2%
Total equity$45.2M+28.1%
Total assets$75.0M+16.7%

Cash flow

See full
Operating cash flow$1.6M+488%
CapEx$112.0K-37.8%
Free cash flow$1.5M

Valuation

See full
Market cap$195.81M+39.3%
Enterprise value$201.8M+34.4%
P/E16.3×+0.7×
P/S2.6×+0.5×

Profitability

See full
Gross margin27.8%-3.6pp
Operating margin14.5%-3.8pp
Net margin16.1%+1.5pp
FCF margin-3.8%+3.2pp

Returns & leverage

See full
Return on equity29.8%+1.5pp
Debt / equity0.4×0.0×
Current ratio3.7×+0.9×

Where this comes from

Reported directly by Pro-Dex, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Pro-Dex, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pro-Dex, Inc.'s common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pro-Dex, Inc.'s common stock, shares issued (in shares)?
Pro-Dex, Inc. (PDEX) reported common stock, shares issued (in shares) of $3.2M in Q1 2026.
How has Pro-Dex, Inc.'s common stock, shares issued (in shares) changed year-over-year?
Pro-Dex, Inc.'s common stock, shares issued (in shares) decreased by 2.0% year-over-year, from $3.26M to $3.2M.
What is the long-term trend for Pro-Dex, Inc.'s common stock, shares issued (in shares)?
Over 4 years (2021 to 2025), Pro-Dex, Inc.'s common stock, shares issued (in shares) has grown at a -2.7% compound annual growth rate (CAGR), from $3.65M to $3.26M.